Cell and Gene Therapy Catapult

#Cell and gene therapy #Cell and Gene Therapy Catapult #Life sciences

New data shows promising cell and gene therapy industry across the UK  

The Cell and Gene Therapy Catapult (CGT Catapult) has published new data in their 2021 Cell and Gene Therapy GMP manufacturing report and 2021 UK cell and gene therapy skills demand report. These reports highlight the continued growth across the UK’s Advanced Therapy Medicinal Product (ATMP) manufacturing capacity and… Read More

#News #Trending News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Collaboration #Drug discovery

CGT Catapult’s creating opportunities in UK cell and gene therapy 

The Cell and Gene Therapy (CGT) Catapult has today published its Annual Review 2021, highlighting its key initiatives and impact in creating opportunities and investment in the UK cell and gene therapy industry.  2021 has reportedly emphasised the strength of the UK cell and gene therapy industry which experienced… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Drug delivery

Collaboration creates novel approach to the advanced therapy industry 

The Cell and Gene Therapy Catapult (CGT Catapult) and Deep Science Ventures have partnered to address barriers in the ATMP industry, create new companies and deliver better patient outcomes.  Recent advances in cell and gene therapies promise potential cures to devastating diseases. However, major hurdles still need to be… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Gene therapy #Neurodegenerative disorders #Research

Gene therapy enables new treatments for neurodegenerative diseases

The University of Sheffield and the Cell and Gene Therapy Catapult have launched a gene therapy programme which could pave the way for novel treatments for neurodegenerative diseases. The research has been awarded £513,141 from LifeArc and the Motor Neurone Disease Association to test the feasibility and efficiency of a… Read More

#News

#Bioscience #Biotechnology #Cell and gene therapy #Cell and Gene Therapy Catapult #Drug development #Life sciences #Research

GSK unveils plan for one of Europe’s largest life science campuses

GSK has announced that it planning to develop its research & development site in Stevenage, UK,  into one of Europe’s largest clusters for biotechnology and early-stage life science companies. The concept has been developed in partnership with Stevenage Bioscience Catalyst (SBC), among others and would build on GSK’s existing presence,… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Cell therapy

CGT Catapult to expand to Edinburgh BioQuarter

The Cell and Gene Therapy Catapult (CGT Catapult) is setting up offices and laboratories in Edinburgh, Scotland. With this expansion, CGT Catapult aims to provide additional, regionally focused support to the cell and gene therapy sector to accelerate product development, clinical trials and adoption. CGT Catapult Edinburgh is a collaboration… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Life sciences

Horiba joins cell and gene therapy consortium

Horiba has announced its participation in a new consortium formed to accelerate the development of process analytical technologies (PAT) in cell and gene therapy manufacturing. Horiba’s new A-TEEM Molecular Fingerprinting technology has shown great promise for fast QC/QA of complex biological systems and is a core technology being assessed for… Read More

#News

#Cell and gene therapy #Cell and Gene Therapy Catapult #Clinical trials

GSK expands trial manufacturing for cell and gene therapy

Cell and Gene Therapy Catapult (CGT Catapult) has announced that GSK will leverage the CGT Catapult Stevenage facility in the UK to perform GMP cell processing to accelerate its cell and gene therapy pipeline for clinical trials. Through this agreement, GSK will improve its GMP cell processing network to advance… Read More

#News

#ATMP #Cell and gene therapy #Cell and Gene Therapy Catapult #Clinical trials

Report cites UK as internationally attractive for development of cell and gene therapies

The Cell and Gene Therapy Catapult (CGT Catapult) has published today the 2020 Advanced Therapy Medicinal Product (ATMP) clinical trials database and report, which show a marked 20% growth in the number of ATMP clinical trials across the UK. The number of commercially sponsored trials has shown a dramatic surge… Read More

#Editor's Choice #News

#Cell and Gene Therapy Catapult #Cell therapy #Gene therapy

Funding to UK cell and gene therapy training centre to strengthen skills pipeline

The Cell and Gene Therapy Catapult (CGT Catapult) and Hertfordshire Local Enterprise Partnership (LEP) in the UK have announced that a new cell and gene therapy integration laboratory at the CGT Catapult facility in Stevenage will be part-funded by the government’s Getting Building Fund. The new laboratory will be exclusively… Read More

#Editor's Choice #News

#Cell and Gene Therapy Catapult #Cell therapy #Gene therapy

High potential opportunity zone named for cell and gene therapy

The UK Department for International Trade (DIT) has classified Stevenage in the UK, as a High Potential Opportunity (HPO) zone in recognition of its thriving cell and gene therapy cluster of national and international significance. The successful HPO nomination was made by Hertfordshire Local Enterprise Partnership (LEP) and is expected… Read More

#News